Solvonis Raises £1.3 Million

New institutional investment supports defined milestones across SVN-001, SVN-002 and SVN-015; Turner Pope appointed corporate broker

LONDON - 25 August 2026 - Solvonis Therapeutics plc (LSE: SVNS), a late clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, is pleased to announce that it has conditionally raised gross proceeds of £1.3 million through a placing of 1,083,333,333 new Ordinary Shares of £0.001 each (the "Placing Shares") with new and existing investors at a placing price of £0.0012 per Placing Share (the "Issue Price") (the "Fundraising").

The Fundraising includes participation from a noted UK institutional investor as a new entrant to the Company's shareholder register.

Turner Pope Investments (TPI) Limited ("Turner Pope") acted as sole bookrunner to the Fundraising and has been appointed as the Company's corporate broker with immediate effect.

The net proceeds of the Fundraising, together with the Company's existing resources, will principally support:

• the assessment and potential addition of selected international sites, including sites in the European Union, to progress the ongoing SVN-001 Phase 3 study
• the advancement of SVN-002 towards an Investigational New Drug ("IND") submission and Phase 2b readiness in the United States; and
• the progression of SVN-015 alongside the US National Institute on Drug Abuse ("NIDA").

Anthony Tennyson, Chief Executive Officer of Solvonis, commented, "This fundraising supports clear next steps across our three priority programmes. We will assess adding selected EU sites to the SVN-001 Phase 3 study, advance SVN-002 towards US Phase 2b readiness, and progress SVN-015 alongside NIDA.

"We are also pleased to welcome a new and renowned institutional investor and to appoint Turner Pope as corporate broker following its role as sole bookrunner. The Board believes that the addition of new institutional capital is an important development as Solvonis advances its clinical and preclinical pipeline and broadens engagement with the UK investment community."

Use of Proceeds

The net proceeds of the Fundraising, together with the Company's existing resources, will principally be applied as follows.

SVN-001 - potential addition of international sites to progress Phase 3

SVN-001 is Solvonis' investigational combination treatment for severe Alcohol Use Disorder ("AUD"), comprising intravenous ketamine together with a proprietary, manualised relapse-prevention cognitive behavioural therapy.

The programme is currently being evaluated in an ongoing Phase 3 clinical study in the United Kingdom.

The Company intends to assess and, subject to the agreement of its study partners and the necessary regulatory, ethics and operational approvals, seek to add selected international sites to the study, including sites within the European Union.

The objective would be to include EU patient data within the overall Phase 3 dataset, broaden its geographic representation and potentially strengthen future regulatory submissions and commercial discussions in selected European markets.

The Fundraising will support the feasibility, regulatory and operational work required to assess and prepare for the proposed expansion.

SVN-002 - progressing towards a U.S. IND and Phase 2b readiness

SVN-002 is Solvonis' proprietary esketamine oral thin-film formulation being developed as a supervised, clinic-administered treatment for moderate-to-severe AUD in the United States.

The programme is being advanced under a planned FDA 505(b)(2) regulatory pathway, with the objective of establishing a scientific bridge to an approved intranasal esketamine reference product.

In June 2026, the Company announced positive pharmacokinetic data from its preclinical bridging study, providing important support for the proposed scientific bridge.

The Fundraising will support:

• completion of the remaining work intended to establish the scientific bridge;
• further engagement with the US Food and Drug Administration regarding the planned IND and any remaining nonclinical and toxicology requirements; and
• subject to supportive results and FDA feedback, completion of the targeted IND-enabling work and preparation of the IND submission.

The objective is to position SVN-002 for Phase 2b readiness in the United States.

SVN-015 - progression alongside NIDA

SVN-015 is Solvonis' proprietary discovery-stage compound being developed initially for stimulant use disorders, including methamphetamine and cocaine use disorders.

In August 2026, the Company announced that NIDA had selected SVN-015 to advance into further evaluation under its Addiction Treatment Discovery Program following encouraging initial cardiac ion-channel and broader off-target screening results.

The next stage is expected to include further confirmatory and in vivo studies funded and undertaken through NIDA's programme. NIDA's support does not constitute a cash grant to Solvonis, and the Company retains ownership of SVN-015 and its associated intellectual property.

The Fundraising will support Solvonis' complementary programme-management, data-assessment and development-planning activities.

General working capital

The balance of the net proceeds will be applied to meet general working capital requirements and the costs associated with delivering the programme activities described above.

Appointment of Corporate Broker

Turner Pope acted as sole bookrunner to the Fundraising and has been appointed as the Company's corporate broker with immediate effect.

Turner Pope replaces Singer Capital Markets. The Board would like to thank Singer Capital Markets for its support and service to the Company during its tenure as broker.

Details of the Fundraising

Placing Shares

The Company is proposing to issue a total of 1,083,333,333 Placing Shares at £0.0012 per share, raising gross proceeds of £1.3 million. The Fundraising is being conducted within the Company's existing share authorities.

The Issue Price represents a discount of approximately 14 per cent. to the price of £0.0014 per existing Ordinary Share, being the Closing Price on the last trading day immediately preceding the date of this announcement.

Fee Shares

The Company has agreed to settle fees for services provided to the Company amounting to £15,000 through the issue of 10,000,000 new ordinary shares of £0.0001 each at an issue price of £0.0015 per share.

Admission and Total Voting Rights

Application will be made for the Placing Shares and Fee Shares to be admitted to trading on the Main Market of the London Stock Exchange and to listing in the FCA's Official List Equity Shares (transition) category ("Admission").

It is expected that Admission will become effective and that dealings in the Placing and Fee Shares will commence at 8.00 a.m. on or around 28 August 2026.

Following Admission, the Company's enlarged issued ordinary share capital will comprise 7,899,736,826 ordinary shares of £0.001 each. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Broker Warrants

As part of its fee arrangements with the Company, Turner Pope is being granted warrants to subscribe for 78,333,333 new Ordinary Shares at the Issue Price, in whole or in part, at any time in the 5 years from Admission (the "Broker Warrants"). The Broker Warrants are freely transferable.

Adviser Warrants

As part of a separate adviser engagement, a consultant to the Company is being granted warrants to subscribe for 30,000,000 new Ordinary Shares at the Issue Price, in whole or in part, at any time in the 5 years from Admission (the "Adviser Warrants"). The Adviser Warrants are freely transferable.

Orana Warrants

As part of its fee arrangements for the provision of its accounting services to the Company, Orana Corporate is being granted warrants to subscribe for 25,000,000 new Ordinary Shares at the Issue Price pursuant to the key terms set out below:

• Exercise period: 5 years from the date of Admission
• Vesting conditions:

Information to Distributors

UK Product Governance Requirements

Solely for the purposes of the Product Governance requirements contained within Chapter 3 of the FCA Handbook Product Intervention and Product Governance Sourcebook (the "UK Product Governance Requirements") and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the UK Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process, which has determined that the Placing Shares are: (i) compatible with an end target market of investors who meet the criteria of professional clients and eligible counterparties, each as defined in the FCA Handbook Conduct of Business Sourcebook; and (ii) eligible for distribution through all distribution channels as are permitted by UK Product Governance Requirements (the "UK Target Market Assessment"). Notwithstanding the UK Target Market Assessment, distributors should note that: the price of the Placing Shares may decline and investors could lose all or part of their investment; the Placing Shares offer no guaranteed income and no capital protection; and an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom.

The UK Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Fundraising. Furthermore, it is noted that, notwithstanding the UK Target Market Assessment, Turner Pope will only procure investors who meet the criteria of professional clients and eligible counterparties.

EU Product Governance Requirements

1. Solely for the purposes of the product governance requirements contained within (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"), (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II and (c) local implementing measures (together the "EU Product Governance Requirements") and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the EU Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to product approval process, which has determined that the Placing Shares are: (i) compatible with an end target market of (a) investors who meet the criteria of professional clients and (b) eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by EU Product Governance Requirements (the "EU Target Market Assessment"). Notwithstanding the EU Target Market Assessment, distributors should note that: the price of the Placing Shares may decline and investors could lose all or part of their investment; the Placing Shares offer no guaranteed income and no capital protection; and an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom.

• The EU Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Fundraising. Furthermore, it is noted that, notwithstanding the EU Target Market Assessment, Turner Pope will only procure investors who meet the criteria of professional clients and eligible counterparties.
• Each distributor is responsible for undertaking its own target market assessment in respect of the Placing Shares and determining appropriate distribution channels.